mRNA-Based Therapeutics Summit Europe 2025

Connect with our team of experts during the mRNA-Based Therapeutics Summit Europe in Frankfurt, Germany (28-30 January 2025).

Intertek can support your mRNA medicines development from early-stage characterization to late-stage development and commercialisation. We provide mRNA analytical development including testing for identity, quantity, quality, purity, potency, and process related impurities. We also provide analytical characterisation of liposome and LNP delivery technologies and extractables and leachables for pharmaceutical container closure systems.

Whilst mRNA drugs or vaccines are specific in their mode of action and are typically administered via sub-cutaneous or intravenous routes, the potential for inhaled or intranasal administration presents a more desirable mode of self-administration, resulting in an improved patient experience and compliance. Our scientists provide complete development solutions for inhaled or nasal delivery including formulation, device selection, compatibility, and analytical development from both the molecule (structure, physicochemical properties, potency) and delivery performance aspects (delivered dose, delivery rate, aerodynamic droplet size distribution, etc). 

Connect with our team to arrange a meeting.

Our mRNA Analytical Development Resources:

Find out more about our drug development and drug delivery expertise by accessing our technical resources below. 

Brochure Download - mRNA Vaccine and Therapeutic Products Analytical Development Services

Presentation - Development Strategies for Inhaled and Nasal Oligonucleotide and mRNA Products

On-Demand Webinar - Superhero Analytics - Understanding the Fantastic Four: Capping Efficiency, Sequencing, Poly-A Tail, dsRNA

Learn more about the event: 4th Annual mRNA-Based Therapeutics Summit Europe

Date: 28th-30th January, 2025 | Frankfurt, Germany

VIDEO mRNA Characterisation, Analysis & GMP Testing Services